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(57) ABSTRACT 
Microneedle devices are provided for transport of therapeu-
tic and biological molecules across tissue barriers and for 
use as microflameholders. In a preferred embodiment for 
transport across tissue, the microneedles are formed of a 
biodegradable polymer. Methods of making these devices, 
which can include hollow and/or porous microneedles, are 
also provided. A preferred method for making a microneedle 
includes forming a micromold having sidewalls which 
define the outer surface of the microneedle, electroplating 
the sidewalls to form the hollow microneedle, and then 
removing the micromold from the microneedle. In a pre-
ferred method of use, the microneedle device is used to 
deliver fluid material into or across a biological barrier from 
one or more chambers in fluid connection with at least one 
of the microneedles. The device preferably further includes 
a means for controlling the flow of material through the 
microneedles. Representative examples of these means 
include the use of permeable membranes, fracturable imper-
meable membranes, valves, and pumps. 
24 Claims, 7 Drawing Sheets 
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MICRONEEDLE DEVICES AND METHODS 
OF MANUFACTURE AND USE THEREOF 
CROSS-REFERENCE TO RELATED 
APPLICATIONS 
This is a continuation-in-part of U.S. Ser. No. 09/095,221, 
filed Jun. 10, 1998 now U.S. Pat. No. 6,193,700. 
STATEMENT REGARDING FEDERALLY 
SPONSORED RESEARCH 
The government has certain rights in this invention by 
virtue of Grant Number BES-9624832 awarded by the U.S. 
National Science Foundation to Mark R. Prausnitz, and by 
virtue of Contract Number DABT63-95-C-0114 awarded by 
the U.S. Defense Advanced Research Projects Agency 
(DARPA). 
BACKGROUND OF THE INVENTION 
This invention is generally in the field of devices for the 
transport of therapeutic or biological molecules across tissue 
barriers, such as for drug delivery. 
Numerous drugs and therapeutic agents have been devel-
oped in the battle against disease and illness. However, a 
frequent limitation of these drugs is their delivery: how to 
transport drugs across biological barriers in the body (e.g., 
the skin, the oral mucosa, the blood-brain barrier), which 
normally do not transport drugs at rates that are therapeu-
tically useful or optimal. 
Drugs are commonly administered orally as pills or 
capsules. However, many drugs cannot be effectively deliv-
ered in this manner, due to degradation in the gastrointestinal 
tract and/or elimination by the liver. Moreover, some drugs 
cannot effectively diffuse across the intestinal mucosa. 
Patient compliance may also be a problem, for example, in 
therapies requiring that pills be taken at particular intervals 
over a prolonged time. 
2 
the necessary physiochemical properties to be effectively 
delivered through the skin by passive diffusion. 
Iontophoresis, electroporation, ultrasound, and heat (so-
called active systems) have been used in an attempt to 
5 improve the rate of delivery. While providing varying 
degrees of enhancement, these techniques are not suitable 
for all types of drugs, failing to provide the desired level of 
delivery. In some cases, they are also painful and inconve-
nient or impractical for continuous controlled drug delivery 
10 over a period of hours or days. Attempts have been made to 
design alternative devices for active transfer of drugs, or 
analyte to be measured, through the skin. 
For example, U.S. Pat. No. 5,879,326 to Godshall et al. 
and PCT WO 96/37256 by Silicon Microdevices, Inc. dis-
15 close a transdermal drug delivery apparatus that includes a 
cutter portion having a plurality of microprotrusions, which 
have straight sidewalls, extending from a substrate that is in 
communication with a drug reservoir. In operation, the 
microprotrusions penetrate the skin until limited by a stop 
20 region of the substrate and then are moved parallel to the 
skin to create incisions. Because the microprotrusions are 
dragged across the skin, the device creates a wound suffi-
ciently large to be a site of infection. Channels in the 
substrate adjacent to the microprotrusions allow drug from 
25 the reservoir to flow to the skin near the area disrupted by the 
microprotrusions. Merely creating a wound, rather than 
using a needle which conveys drug through an enclosed 
channel into the site of administration, also creates more 
30 
variability in dosage. 
U.S. Pat. No. 5,250,023 to Lee et al. discloses a trans-
dermal drug delivery device, which includes a plurality of 
skin needles having a diameter in the range of 50 to 400 µm. 
The skin needles are supported in a water-swellable polymer 
substrate through which a drug solution permeates to contact 
35 the surface of the skin. An electric current is applied to the 
device to open the pathways created by the skin needles, 
following their withdrawal from the skin upon swelling of 
the polymer substrate. Another common technique for delivering drugs across a 
biological barrier is the use of a needle, such as those used 
with standard syringes or catheters, to transport drugs across 
(through) the skin. While effective for this purpose, needles 
generally cause pain; local damage to the skin at the site of 
insertion; bleeding, which increases the risk of disease 
transmission; and a wound sufficiently large to be a site of 
infection. The withdrawal of bodily fluids, such as for 
diagnostic purposes, using a conventional needle has these 
same disadvantages. Needle techniques also generally 
require administration by one trained in its use. The needle 
technique also is undesirable for long term, controlled 50 
continuous drug delivery. 
PCT WO 93/17754 by Gross et al. discloses another 
40 transdermal drug delivery device that includes a housing 
having a liquid drug reservoir and a plurality of tubular 
elements for transporting liquid drug into the skin. The 
tubular elements may be in the form of hollow needles 
having inner diameters of less than 1 mm and an outer 
45 diameter of 1.0 mm. 
While each of these devices has potential use, there 
remains a need for better drug delivery devices, which make 
smaller incisions, deliver drug with greater efficiency 
(greater drug delivery per quantity applied) and less vari-
ability of drug administration, and/or are easier to use. 
It is therefore an object of the present invention to provide 
a microneedle device for relatively painless, controlled, safe, 
convenient transdermal delivery of a variety of drugs. 
It is another object of the present invention to provide a 
microneedle device for controlled sampling of biological 
fluids in a minimally-invasive, painless, and convenient 
manner. 
Similarly, current methods of sampling biological fluids 
are invasive and suffer from the same disadvantages. For 
example, needles are not preferred for frequent routine use, 
such as sampling of a diabetic's blood glucose or delivery of 55 
insulin, due to the vascular damage caused by repeated 
punctures. No alternative methodologies are currently in 
use. Proposed alternatives to the needle require the use of 
lasers or heat to create a hole in the skin, which is 
inconvenient, expensive, or undesirable for repeated use. 
It is still another object of the present invention to provide 
60 a hollow microneedle array for use in delivery or sensing of 
drugs or biological fluids or molecules. An alternative delivery technique is the transdermal 
patch, which usually relies on diffusion of the drug across 
the skin. However, this method is not useful for many drugs, 
due to the poor permeability (i.e. effective barrier properties) 
of the skin. The rate of diffusion depends in part on the size 65 
and hydrophilicity of the drug molecules and the concen-
tration gradient across the stratum corneum. Few drugs have 
SUMMARY OF THE INVENTION 
Micro needle devices for transport of molecules, including 
drugs and biological molecules, across tissue, and methods 
for manufacturing the devices, are provided. The micron-
eedle devices permit drug delivery or removal of body fluids 
US 6,334,856 Bl 
3 
at clinically relevant rates across skin or other tissue barriers, 
with minimal or no damage, pain, or irritation to the tissue. 
Microneedles can be formed of biodegradable or non-
biodegradable polymeric materials or metals. In a preferred 
embodiment, the microneedles are formed of a biodegrad- 5 
able polymer. In another preferred embodiment, the device 
includes a means for temporarily securing the microneedle 
device to the biological barrier to facilitate transport. 
Methods are provided for making porous or hollow 
microneedles. A preferred method for making a micro needle 10 
includes forming a micromold having sidewalls which 
define the outer surface of the microneedle. The micromold 
can be formed, for example, by photolithographically defin-
ing one or more holes in a substrate, or by laser based cutting 
(either serially or by using lithographic projection), or by 15 
using a mold-insert. In a preferred embodiment, the method 
includes electroplating the sidewalls to form the hollow 
microneedle, and then removing the micromold from the 
microneedle. 
The microneedle device is useful for delivery of fluid 20 
material into or across a biological barrier wherein the fluid 
material is delivered from one or more chambers in fluid 
connection with at least one of the microneedles. The device 
preferably further includes a means for controlling the flow 
of material through the microneedles. Representative 25 
examples of these means include the use of permeable 
membranes, fracturable impermeable membranes, valves, 
and pumps, and electrical means. 
4 
of a cell or cells). The biological barriers can be in humans 
or other types of animals, as well as in plants, insects, or 
other organisms, including bacteria, yeast, fungi, and 
embryos. 
The microneedle devices can be applied to tissue inter-
nally with the aid of a catheter or laparoscope. For certain 
applications, such as for drug delivery to an internal tissue, 
the devices can be surgically implanted. 
The microneedle device disclosed herein is typically 
applied to skin. The stratum corneum is the outer layer, 
generally between 10 and 50 cells, or between 10 and 20 µm 
thick. Unlike other tissue in the body, the stratum corneum 
contains "cells" (called keratinocytes) filled with bundles of 
cross-linked keratin and keratohyalin surrounded by an 
extracellular matrix of lipids. It is this structure that is 
believed to give skin its barrier properties, which prevents 
therapeutic transdermal administration of many drugs. 
Below the stratum corneum is the viable epidermis, which is 
between 50 and 100 µm thick. The viable epidermis contains 
no blood vessels, and it exchanges metabolites by diffusion 
to and from the dermis. Beneath the viable epidermis is the 
dermis, which is between 1 and 3 mm thick and contains 
blood vessels, lymphatics, and nerves. 
2. The Microneedle Device 
The microneedle devices disclosed herein include a sub-
strate; one or more microneedles; and, optionally, a reservoir 
for delivery of drugs or collection of analyte, as well as 
pump(s), sensor(s), and/or microprocessor(s) to control the 
BRIEF DESCRIPTION OF THE DRAWINGS 30 interaction of the foregoing. 
FIG. la is a side elevational view of a preferred embodi-
ment of the microneedle device inserted into human skin. 
a. Substrate 
FIG. lb is a diagram of one embodiment of microneedles. 
FIGS. 2a-e are side cross-sectional views of a method for 35 
making microneedles. 
The substrate of the device can be constructed from a 
variety of materials, including metals, ceramics, 
semiconductors, organics, polymers, and composites. The 
substrate includes the base to which the microneedles are 
attached or integrally formed. A reservoir may also be 
attached to the substrate. 
FIGS. 3a-g are side cross-sectional views of a method for 
making a hollow microneedle. 
FIGS. 4a through 4d are side cross-sectional views illus- 40 
trating a preferred method for making hollow microneedles. b. Microneedle 
FIGS. Sa through 5d are side cross-sectional views illus-
trating a preferred method for making hollow silicon micro-
tubes. 
The microneedles of the device can be constructed from 
FIGS. 6a through 6e are side cross-sectional views illus- 45 
trating a preferred method for making hollow metal micro-
tubes. 
a variety of materials, including metals, ceramics, 
semiconductors, organics, polymers, and composites. Pre-
ferred materials of construction include pharmaceutical 
grade stainless steel, gold, titanium, nickel, iron, gold, tin, 
chromium, copper, alloys of these or other metals, silicon, 
silicon dioxide, and polymers. Representative biodegradable 
polymers include polymers of hydroxy acids such as lactic 
FIGS. 7a through 7d are side cross-sectional views illus-
trating a preferred method for making tapered metal micron-
eedles. 
FIGS. Sa through Sd are side cross-sectional views illus-
trating a method for making tapered microneedles using 
laser-formed molds. 
FIGS. 9a through 9f are side cross-sectional views illus-
trating a second method for making tapered microneedles 
using laser-formed molds. 
DETAILED DESCRIPTION OF THE 
INVENTION 
1. Biological Barriers 
The devices disclosed herein are useful in transport of 
material into or across biological barriers including the skin 
(or parts thereof); the blood-brain barrier; mucosal tissue 
(e.g., oral, nasal, ocular, vaginal, urethral, gastrointestinal, 
respiratory); blood vessels; lymphatic vessels; or cell mem-
branes (e.g., for the introduction of material into the interior 
50 acid and glycolic acid polylactide, polyglycolide, 
polylactide-co-glycolide, and copolymers with PEG, 
polyanhydrides, poly( ortho )esters, polyurethanes, poly 
(butyric acid), poly(valeric acid), and poly(lactide-co-
caprolactone ). Representative non-biodegradable polymers 
55 include polycarbonate, polymethacrylic acid, ethylenevinyl 
acetate, polytetrafluorethylene (TEFLON™), and polyes-
ters. 
Generally, the microneedles should have the mechanical 
strength to remain intact for delivery of drugs, or serve as a 
60 conduit for the collection of biological fluid, while being 
inserted into the skin, while remaining in place for up to a 
number of days, and while being removed. In embodiments 
where the microneedles are formed of biodegradable 
polymers, however, this mechanical requirement is less 
65 stringent, since the microneedles or tips thereof can break 
off, for example in the skin, and will biodegrade. 
Nonetheless, even a biodegradable microneedle still needs 
US 6,334,856 Bl 
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contours of the biological barrier, such as the skin, vessel 
walls, or the eye, to which the device is applied. A flexible 
device will facilitate more consistent penetration during use, 
since penetration can be limited by deviations in the attach-
to remain intact at least long enough for the microneedle to 
serve its intended purpose (e.g, its conduit function). 
Therefore, biodegradable microneedles can provide an 
increased level of safety, as compared to nonbiodegradable 
ones. The microneedles should be sterilizable using standard 
methods. 
5 ment surface. For example, the surface of human skin is not 
fiat due to dermatoglyphics (i.e. tiny wrinkles) and hair. 
The microneedles can be formed of a porous solid, with 
or without a sealed coating or exterior portion, or hollow. As 
used herein, the term "porous" means having pores or voids 
throughout at least a portion of the microneedle structure, 10 
sufficiently large and sufficiently interconnected to permit 
passage of fluid and/or solid materials through the micron-
eedle. As used herein, the term "hollow" means having one 
or more substantially annular bores or channels through the 
interior of the microneedle structure, having a diameter 15 
sufficiently large to permit passage of fluid and/or solid 
materials through the microneedle. The annular bores may 
extend throughout all or a portion of the needle in the 
direction of the tip to the base, extending parallel to the 
direction of the needle or branching or exiting at a side of the 20 
needle, as appropriate. A solid or porous micro needle can be 
hollow. One of skill in the art can select the appropriate 
porosity and/or bore features required for specific applica-
tions. For example, one can adjust the pore size or bore 
diameter to permit passage of the particular material to be 25 
transported through the microneedle device. 
The microneedles can have straight or tapered shafts. A 
hollow microneedle that has a substantially uniform 
diameter, which needle does not taper to a point, is referred 
to herein as a "microtube." As used herein, the term 30 
"microneedle" includes both microtubes and tapered needles 
unless otherwise indicated. In a preferred embodiment, the 
diameter of the micro needle is greatest at the base end of the 
microneedle and tapers to a point at the end distal the base. 
The microneedle can also be fabricated to have a shaft that 35 
includes both a straight (untapered) portion and a tapered 
portion. 
c. Reservoir 
The microneedle device may include a reservoir in com-
munication with the microneedles. The reservoir can be 
attached to the substrate by any suitable means. In a pre-
ferred embodiment, the reservoir is attached to the back of 
the substrate (opposite the micro needles) around the 
periphery, using an adhesive agent (e.g., glue). A gasket may 
also be used to facilitate formation of a fluid-tight seal. 
In a preferred embodiment, the reservoir contains drug, 
for delivery through the microneedles. The reservoir may be 
a hollow vessel, a porous matrix, or a solid form including 
drug which is transported therefrom. The reservoir can be 
formed from a variety of materials that are compatible with 
the drug or biological fluid contained therein. Preferred 
materials include natural and synthetic polymers, metals, 
ceramics, semiconductors, organics, and composites. 
The microneedle device can include one or a plurality of 
chambers for storing materials to be delivered. In the 
embodiment having multiple chambers, each can be in fluid 
connection with all or a portion of the microneedles of the 
device array. In one embodiment, at least two chambers are 
used to separately contain drug (e.g., a lyophilized drug, 
such as a vaccine) and an administration vehicle (e.g., 
saline) in order to prevent or minimize degradation during 
storage. Immediately before use, the contents of the cham-
bers are mixed. Mixing can be triggered by any means, 
including, for example, mechanical disruption (i.e. punctur-
ing or breaking), changing the porosity, or electrochemical 
degradation of the walls or membranes separating the cham-
bers. In another embodiment, a single device is used to 
deliver different drugs, which are stored separately in dif-The microneedles can be formed with shafts that have a 
circular cross-section in the perpendicular, or the cross-
section can be non-circular. For example, the cross-section 
of the microneedle can be polygonal (e.g. star-shaped, 
square, triangular), oblong, or another shape. The shaft can 
have one or more bores. The cross-sectional dimensions 
typically are between about 10 nm and 1 mm, preferably 
between 1 micron and 200 microns, and more preferably 
between 10 and 100 µm. The outer diameter is typically 
between about 10 µm and about 100 µm, and the inner 
diameter is typically between about 3 µm and about 80 µm. 
40 ferent chambers. In this embodiment, the rate of delivery of 
each drug can be independently controlled. 
The length of the micro needles typically is between about 
In a preferred embodiment, the reservoir should be in 
direct contact with the microneedles and have holes through 
which drug could exit the reservoir and flow into the interior 
45 of hollow or porous microneedles. In another preferred 
embodiment, the reservoir has holes which permit the drug 
to transport out of the reservoir and onto the skin surface. 
From there, drug is transported into the skin, either through 
hollow or porous microneedles, along the sides of solid 
50 microneedles, or through pathways created by microneedles 
in the skin. 1 µm and 1 mm, preferably between 10 microns and 500 
microns, and more preferably between 30 and 200 µm. The 
length is selected for the particular application, accounting 
for both an inserted and uninserted portion. An array of 
microneedles can include a mixture of micro needles having, 55 
for example, various lengths, outer diameters, inner 
diameters, cross-sectional shapes, and spacings between the 
microneedles. 
d. Transport Control Components 
The microneedle device also must be capable of trans-
porting material across the barrier at a useful rate. For 
example, the microneedle device must be capable of deliv-
ering drug across the skin at a rate sufficient to be thera-
peutically useful. The device may include a housing with 
microelectronics and other micromachined structures to The microneedles can be oriented perpendicular or at an 
angle to the substrate. Preferably, the microneedles are 
oriented perpendicular to the substrate so that a larger 
density of microneedles per unit area of substrate can be 
provided. An array of microneedles can include a mixture of 
microneedle orientations, heights, or other parameters. 
In a preferred embodiment of the device, the substrate 
and/or microneedles, as well as other components, are 
formed from flexible materials to allow the device to fit the 
60 control the rate of delivery either according to a prepro-
grammed schedule or through active interface with the 
patient, a healthcare professional, or a biosensor. The rate 
can be controlled by manipulating a variety of factors, 
including the characteristics of the drug formulation to be 
65 delivered (e.g., its viscosity, electric charge, and chemical 
composition); the dimensions of each microneedle (e.g., its 
outer diameter and the area of porous or hollow openings); 
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the number of micro needles in the device; the application of 
a driving force (e.g., a concentration gradient, a voltage 
gradient, a pressure gradient); and the use of a valve. 
The rate also can be controlled by interposing between the 
drug in the reservoir and the opening(s) at the base end of the 5 
microneedle polymeric or other materials selected for their 
diffusion characteristics. For example, the material compo-
sition and layer thickness can be manipulated using methods 
known in the art to vary the rate of diffusion of the drug of 
interest through the material, thereby controlling the rate at 10 
which the drug flows from the reservoir through the micron-
eedle and into the tissue. 
Transportation of molecules through the micro needles can 
8 
sensors can be located on the microneedle surface, inside a 
hollow or porous microneedle, or inside a device in com-
munication with the body tissue via the microneedle (solid, 
hollow, or porous). These microneedle biosensors can 
include four classes of principal transducers: potentiometric, 
amperometric, optical, and physiochemical. An amperomet-
ric sensor monitors currents generated when electrons are 
exchanged between a biological system and an electrode. 
Blood glucose sensors frequently are of this type. 
The microneedle may function as a conduit for fluids, 
solutes, electric charge, light, or other materials. In one 
embodiment, hollow microneedles can be filled with a 
substance, such as a gel, that has a sensing functionality 
associated with it. In an application for sensing based on 
be controlled or monitored using, for example, various 
combinations of valves, pumps, sensors, actuators, and 
microprocessors. These components can be produced using 
standard manufacturing or microfabrication techniques. 
Actuators that may be useful with the microneedle devices 
disclosed herein include micropumps, microvalves, and 
positioners. In a preferred embodiment, a microprocessor is 
programmed to control a pump or valve, thereby controlling 
the rate of delivery. 
15 binding to a substrate or reaction mediated by an enzyme, 
the substrate or enzyme can be immobilized in the needle 
interior, which would be especially useful in a porous needle 
to create an integral needle/sensor. 
Flow of molecules through the microneedles can occur 
based on diffusion, capillary action, or can be induced using 
conventional mechanical pumps or nonmechanical driving 
forces, such as electroosmosis or electrophoresis, or con-
vection. For example, in electroosmosis, electrodes are 
positioned on the biological barrier surface, one or more 
microneedles, and/or the substrate adjacent the needles, to 
create a convective flow which carries oppositely charged 
ionic species and/or neutral molecules toward or into the 
biological barrier. In a preferred embodiment, the micron-
eedle device is used in combination with another mechanism 
that enhances the permeability of the biological barrier, for 
example by increasing cell uptake or membrane disruption, 
using electric fields, ultrasound, chemical enhancers, 35 
viruses, pH, heat and/or light. 
Wave guides can be incorporated into the microneedle 
20 device to direct light to a specific location, or for dection, for 
example, using means such as a pH dye for color evaluation. 
Similarly, heat, electricity, light or other energy forms may 
be precisely transmitted to directly stimulate, damage, or 
heal a specific tissue or intermediary (e.g., tattoo remove for 
25 dark skinned persons), or diagnostic purposes, such as 
measurement of blood glucose based on IR spectra or by 
chromatographic means, measuring a color change in the 
presence of immobilized glucose oxidase in combination 
with an appropriate substrate. 
Passage of the microneedles, or drug to be transported via 
the microneedles, can be manipulated by shaping the 
microneedle surface, or by selection of the material forming 
30 
th microneedle surface (which could be a coating rather than 
the microneedle per se). For example, one or more grooves 40 
on the outside surface of the microneedles can be used to 
f. Attachment Features 
A collar or flange also can be provided with the device, for 
example, around the periphery of the substrate or the base. 
It preferably is attached to the device, but alternatively can 
be formed as integral part of the substrate, for example by 
forming microneedles only near the center of an "oversized" 
substrate. The collar can also emanate from other parts of the 
device. The collar can provide an interface to attach the 
microneedle array to the rest of the device, and can facilitate 
handling of the smaller devices. 
In a preferred embodiment, the microneedle device 
includes an adhesive to temporarily secure the device to the 
surface of the biological barrier. The adhesive can be essen-
direct the passage of drug, particularly in a liquid state. 
Alternatively, the physical surface properties of the micron-
eedle could be manipulated to either promote or inhibit 
transport of material along the microneedle surface, such as 
by controlling hydrophilicity or hydrophobicity. 
The flow of molecules can be regulated using a wide 
range of valves or gates. These valves can be the type that 
are selectively and repeatedly opened and closed, or they can 
45 tially anywhere on the device to facilitate contact with the 
biological barrier. For example, the adhesive can be on the 
surface of the collar (same side as microneedles), on the 
surface of the substrate between the microneedles (near the 
base of the microneedles), or a combination thereof. 
be single-use types. For example, in a disposable, single-use 50 
drug delivery device, a fracturable barrier or one-way gate 
may be installed in the device between the reservoir and the 
opening of the microneedles. When ready to use, the barrier 
can be broken or gate opened to permit flow through the 
microneedles. Other valves or gates used in the microneedle 55 
devices can be activated thermally, electrochemically, 
mechanically, or magnetically to selectively initiate, 
modulate, or stop the flow of molecules through the needles. 
g. Transdermal Microneedle Device 
FIG. la is a side elevational view of a schematic of a 
preferred embodiment of the microneedle device inserted 
into skin. The device 10 includes an upper portion or 
substrate 11 from which a plurality of microneedles 12 
protrude. The height of the upper portion 11 is between 
about 1 µm and 1 cm, and the width of the upper portion is 
between about 1 mm and 10 cm. The upper portion 11 of the 
device can be solid or hollow, and may include multiple In a preferred embodiment, flow is controlled by using a 
rate-limiting membrane as a "valve." 
The microneedle devices can further include a flowmeter 
or other means to monitor flow through the microneedles 
and to coordinate use of the pumps and valves. 
e. Sensors 
60 compartments. In a preferred embodiment for drug delivery, 
the upper portion 11 contains one or more drugs to be 
delivered. It is also preferred that the upper portion include 
one or more sensors and/or an apparatus (e.g., pump or 
electrode) to drive (provide/direct the force) transport of the 
Useful sensors may include sensors of pressure, 
temperature, chemicals, and/or electromagnetic fields. Bio-
65 drug or other molecules. 
The height (or length) of the micro needles 12 generally is 
between about 1 µm and 1 mm. The diameter and length 
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both affect pain as well as functional properties of the 
needles. In transdermal applications, the "insertion depth" of 
the microneedles 12 is preferably less than about 100 µm, 
more preferably about 30 µm, so that insertion of the 
microneedles 12 into the skin through the stratum corneum s 
14 does not penetrate past the epidermis 16 into the dermis 
18 (as described below), thereby avoiding contacting nerves 
and reducing the potential for causing pain. In such 
applications, the actual length of the microneedles may be 
longer, since the portion of the microneedles distal the tip 10 
may not be inserted into the skin; the uninserted length 
depends on the particular device design and configuration. 
The actual (overall) height or length of micro needles 12 
should be equal to the insertion depth plus the uninserted 
length. lS 
The diameter of each microneedle 12 generally is between 
about 10 nm and 1 mm, and preferably leaves a residual hole 
(following microneedle insertion and withdrawal) of less 
than about 1 µm, to avoid making a hole which would allow 20 
bacteria to enter the penetration wound. The actual micron-
eedle diameter should be larger than 1 µm, since the hole 
likely will contract following withdrawal of the micron-
eedle. The diameter of microneedle 12 more preferably is 
between about 1 µm and 100 µm. Larger diameter and longer 2s 
microneedles are acceptable, so long as the microneedle can 
penetrate the biological barrier to the desired depth and the 
hole remaining in the skin or other tissue following with-
drawal of the microneedle is sufficiently small, preferably 
small enough to exclude bacterial entry. The microneedles 30 
12 can be solid or porous, and can include one or more bores 
connected to upper portion 11. 
3. Methods of Making Microneedle Devices 
10 
The following methods are preferred for making micron-
eedles. 
i. Electrochemical Etching of Silicon 
In this method, electrochemical etching of solid silicon to 
porous silicon is used to create extremely fine (on the order 
of 0.01 µm) silicon networks which can be used as piercing 
structures. This method uses electrolytic anodization of 
silicon in aqueous hydrofluoric acid, potentially in combi-
nation with light, to etch channels into the silicon. By 
varying the doping concentration of the silicon wafer to be 
etched, the electrolytic potential during etching, the incident 
light intensity, and the electrolyte concentration, control 
over the ultimate pore structure can be achieved. The 
material not etched (i.e. the silicon remaining) forms the 
microneedles. This method has been used to produce irregu-
lar needle-type structures measuring tens of nanometers in 
width. 
ii. Plasma Etching 
This process uses deep plasma etching of silicon to create 
microneedles with diameters on the order of 0.1 µm or 
larger. Needles are patterned directly using 
photolithography, rather than indirectly by controlling the 
voltage (as in electrochemical etching), thus providing 
greater control over the final microneedle geometry. 
In this process, an appropriate masking material (e.g., 
metal) is deposited onto a silicon wafer substrate and 
patterned into dots having the diameter of the desired 
microneedles. The wafer is then subjected to a carefully 
controlled plasma based on fluorine/oxygen chemistries to 
etch very deep, high aspect ratio trenches into the silicon. 
See, e.g., Jansen, et al., "The Black Silicon Method IV: The 
Fabrication of Three-Dimensional Structures in Silicon with 
The microneedle devices are made by microfabrication 
processes, by creating small mechanical structures in silicon, 
metal, polymer, and other materials. These microfabrication 
processes are based on well-established methods used to 
make integrated circuits, electronic packages and other 
microelectronic devices, augmented by additional methods 
used in the field of micromachining. The microneedle 
devices can have dimensions as small as a few nanometers 
and can be mass-produced at low per-unit costs. 
3
s High Aspect Ratios for Scanning Probe Microscopy and 
Other Applications," IEEE Proceedings ofMicro Electro 
Mechanical Systems Conference, pp. 88-93 (1995). Those 
regions protected by the metal mask remain and form the 
needles. This method is further described in Example 1 
40 
below. FIG. lb provides a diagram of microneedles fabri-
cated by this method. 
iii. Electroplating 
In this process, a metal layer is first evaporated onto a 
planar substrate. A layer of photoresist is then deposited onto 
a. Microfabrication Processes 4S the metal to form a patterned mold which leaves an exposed-
metal region in the shape of needles. By electroplating onto 
the exposed regions of the metal seed layer, the mold 
bounded by photoresist can be filled with electroplated 
material. Finally, the substrate and photoresist mold are 
Microfabrication processes that may be used in making 
the microneedles disclosed herein include lithography; etch-
ing techniques, such as wet chemical, dry, and photoresist 
removal; thermal oxidation of silicon; electroplating and 
electroless plating; diffusion processes, such as boron, 
phosphorus, arsenic, and antimony diffusion; ion implanta-
tion; film deposition, such as evaporation (filament, electron 
beam, flash, and shadowing and step coverage), sputtering, 
chemical vapor deposition (CVD), epitaxy (vapor phase, 
liquid phase, and molecular beam), electroplating, screen 
printing, lamination, stereolithography, laser machining, and 
laser ablation (including projection ablation). See generally 
Jaeger, Introduction to Microelectronic Fabrication 
(Addison-Wesley Publishing Co., Reading Mass. 1988); 60 
Runyan, et al., Semiconductor Integrated Circuit Processing 
Technology (Addison-Wesley Publishing Co., Reading 
Mass. 1990); Proceedings of the IEEE Micro Electro 
Mechanical Systems Conference 1987-1998; Rai-
Choudhury, ed., Handbook of Microlithography, Microma- 6S 
chining & Micro/ abrication (SPIE Optical Engineering 
Press, Bellingham, Wash. 1997). 
so removed, leaving the finished microneedle array. The 
microneedles produced by this process generally have diam-
eters on the order of 1 µm or larger. See, e.g., Frazier, et al., 
"Two dimensional metallic microelectrode arrays for extra-
cellular stimulation and recording of neurons", IEEE Pro-
ss ceedings of the Micro Electro Mechanical Systems 
Conference, pp. 195-200 (1993). 
iv. Other Processes 
Another method for forming microneedles made of sili-
con or other materials is to use microfabrication techniques 
such as photolithography, plasma etching, or laser ablation 
to make a mold form (A), transferring that mold form to 
other materials using standard mold transfer techniques, 
such as embossing or injection molding (B), and reproduc-
ing the shape of the original mold form (A) using the 
newly-created mold (B) to yield the final microneedles (C). 
Alternatively, the creation of the mold form (A) could be 
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skipped and the mold (B) could be microfabricated directly, 
which could then be used to create the final microneedles 
(C). 
Another method of forming solid silicon microneedles is 
by using epitaxial growth on silicon substrates, as is utilized 
by Containerless Research, Inc. (Evanston, Ill., USA) for its 
products. 
b. Hollow or Porous Microneedles 
In a preferred embodiment, microneedles are made with 
pores or other pathways through which material may be 
transported. The following descriptions outline representa-
tive methods for fabricating either porous or hollow micron-
eedles. 
i. Porous Microneedles 
Rather than having a single, well-defined hole down the 
length of the needle, porous needles are filled with a network 
of channels or pores which allow conduction of fluid or 
energy through the needle shaft. It has been shown that by 
appropriate electrochemical oxidation of silicon, pore arrays 
with high aspect ratios and a range of different pore size 
regimes can be formed; these pore regimes are defined as (1) 
microporous regime with average pore dimensions less than 
2 nm, (2) mesoporous regime with average pore sizes of 
between 2 nm and 50 nm, and (3) macroporous regime with 
pores greater than 50 nm. The mesoporous and macroporous 
regimes are expected to be most useful for drug delivery. 
Two approaches to porous needles are generally available, 
either (a) the silicon wafer is first made porous and then 
etched as described above to form needles or (b) solid 
microneedles are etched and then rendered porous, for 
example, by means of electrochemical oxidation, such as by 
anodization of a silicon substrate in a hydrofluoric acid 
electrolyte. The size distribution of the etched porous struc-
ture is highly dependent on several variables, including 
doping kind and illumination conditions, as detailed in 
Lehmann, "Porous Silicon-A New Material for MEMS", 
IEEE Proceedings of the Micro Electro Mechanical Systems 
Conference, pp. 1-6 (1996). Porous polymer or metallic 
microneedles can be formed, for example, by micromolding 
a polymer containing a volatilizable or leachable material, 
such as a volatile salt, dispersed in the polymer or metal, and 
then volatilizing or leaching the dispersed material, leaving 
a porous polymer matrix in the shape of the microneedle. 
ii. Hollow Needles 
Three-dimensional arrays of hollow microneedles can be 
fabricated, for example, using combinations of dry etching 
processes (Laermer, et al., "Bosch Deep Silicon Etching: 
12 
around the hole. Alternatively, the microneedles and their 
holes can be made simultaneously or holes can be etched 
into existing microneedles. As another option, a microneedle 
form or mold can be made, then coated, and then etched 
5 away, leaving only the outer coating to form a hollow 
microneedle. Coatings can be formed either by deposition of 
a film or by oxidation of the silicon microneedles to a 
specific thickness, followed by removal of the interior 
silicon. Also, holes from the backside of the wafer to the 
10 underside of the hollow needles can be created using a 
front-to-backside infrared alignment followed by etching 
from the backside of the wafer. 
15 
a. Silicon Microneedles 
One method for hollow needle fabrication is to replace the 
solid mask used in the formation of solid needles by a mask 
that includes a solid shape with one or more interior regions 
of the solid shape removed. One example is a "donut-
shaped" mask. Using this type of mask, interior regions of 
20 the needle are etched simultaneously with their side walls. 
Due to lateral etching of the inner side walls of the needle, 
this may not produce sufficiently sharp walls. In that case, 
two plasma etches may be used, one to form the outer walls 
of the microneedle (i.e., the 'standard' etch), and one to form 
25 the inner hollow core (which is an extremely anisotropic 
etch, such as in inductively-coupled-plasma "ICP" etch). For 
example, the ICP etch can be used to form the interior region 
of the needle followed by a second photolithography step 
and a standard etch to form the outer walls of the micron-
30 eedle. FIG. 2a represents a silicon wafer 82 with a patterned 
photoresist layer 84 on top of the wafer 82. The wafer 82 is 
anisotropically etched (FIG. 2b) to form a cavity 86 through 
its entire thickness (FIG. 2c). The wafer 82 is then coated 
with a chromium layer 88 followed by a second photoresist 
35 layer 90 patterned so as to cover the cavity 86 and form a 
circular mask for subsequent etching (FIG. 2d). The wafer 
82 is then etched by a standard etch to form the outer tapered 
walls 92 of the microneedle (FIG. 2e). 
Alternatively, this structure can be achieved by substitut-
40 ing the chromium mask used for the solid microneedles 
described in Example I by a silicon nitride layer 94 on the 
silicon substrate 95 covered with chromium 96, deposited as 
shown in FIG. 3a and patterned as shown in FIG. 3b. Solid 
microneedles are then etched as described in Example 1 as 
45 shown FIG. 3c, the chromium 96 is stripped (FIG. 3d), and 
the silicon 95 is oxidized to form a thin layer of silicon 
dioxide 97 on all exposed silicon surfaces (FIG. 3e). The 
silicon nitride layer 94 prevents oxidation at the needle tip. 
The silicon nitride 94 is then stripped (FIG. 3f), leaving 
50 exposed silicon at the tip of the needle and oxide-covered 
silicon 97 everywhere else. The needle is then exposed to an 
ICP plasma which selectively etches the inner sidewalls of 
the silicon 95 in a highly anisotropic manner to form the 
Improving Uniformity and Etch Rate for Advanced MEMS 
Applications," Micro Electro Mechanical Systems, Orlando, 
Fla., USA, (Jan. 17-21, 1999); Despont et al., "High-
Aspect-Ratio, Ultrathick, Negative-Tone Near-UV Photore- 55 
sist for MEMS", Proc. of IEEE lO'h Annual International 
Workshop on MEMS, Nagoya, Japan, pp. 518-522 (Jan. 
26-30, 1997)); micromold creation in lithographically-
defined and/or laser ablated polymers and selective sidewall 
electroplating; or direct micromolding techniques using 
epoxy mold transfers. 
interior hole of the needle (FIG. 3g). 
Another-method uses the solid silicon needles described 
previously as 'forms' around which the actual needle struc-
tures are deposited. After deposition, the forms are etched 
away, yielding the hollow structures. Silica needles or metal 
needles can be formed using different methods. Silica 
60 needles can be formed by creating needle structures similar 
to the ICP needles described above prior to the oxidation 
described above. The wafers are then oxidized to a con-
trolled thickness, forming a layer on the shaft of the needle 
form which will eventually become the hollow microneedle. 
One or more distinct and continuous pathways are created 
through the interior of microneedles. In a preferred 
embodiment, the microneedle has a single annular pathway 
along the center axis of the microneedle. This pathway can 
be achieved by initially chemically or physically etching the 
holes in the material and then etching away microneedles 
65 The silicon nitride is then stripped and the silicon core 
selectively etched away (e.g., in a wet alkaline solution) to 
form a hollow silica microneedle. 
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laminate is selectively removed using wet etching. Then a 
seed layer, such as Ti/Cu(fi (e.g., 30 nm/200 nm/30 nm), is 
conformally DC sputter-deposited onto the upper surface of 
the epoxy mold and onto the sidewalls of the cylindrical 
5 holes. The seed layer should be electrically isolated from the 
substrate. Subsequently, one or more electroplatable metals 
or alloys, such as Ni, NiFe, Au, Cu, or Ti are electroplated 
onto the seed layer. The surrounding epoxy is then removed, 
leaving microtubes which each have an interior annular hole 
In a preferred embodiment, an array of hollow silicon 
microtubes is made using deep reactive ion etching com-
bined with a modified black silicon process in a conven-
tional reactive ion etcher, as described in Example 3 below. 
First, arrays of circular holes are patterned through photo-
resist into Si02 , such as on a silicon wafer. Then the silicon 
can be etched using deep reactive ion etching (DRIE) in an 
inductively coupled plasma (ICP) reactor to etch deep 
vertical holes. The photoresist was then removed. Next, a 
second photolithography step patterns the remaining Si02 
layer into circles concentric to the holes, leaving ring shaped 
oxide masks surrounding the holes. The photoresist is then 
removed and the silicon wafer again deep silicon etched, 
such that the holes are etched completely through the wafer 
(inside the Si02 ring) and simultaneously the silicon is 15 
etched around the Si02 ring leaving a cylinder. 
10 that extends through the base metal supporting the tubes. 
This latter process can be varied to produce hollow, 
tapered micro needles. After an array of holes is fabricated as 
described above, the photoresist and Si02 layers are 
replaced with conformal DC sputtered chromium rings. The 20 
second ICP etch is replaced with a SFd02 plasma etch in a 
reactive ion etcher (RIE), which results in positively sloping 
outer sidewalls. Henry, et al., "Micromachined Needles for 
the Transdermal Delivery of Drugs," Micro Electro 
Mechanical Systems, Heidelberg, Germany, pp. 494--498 25 
(Jan. 26-29, 1998). 
b. Metal Microneedles 
Metal needles can be formed by physical vapor deposition 
of appropriate metal layers on solid needle forms, which can 30 
be made of silicon using the techniques described above, or 
which can be formed using other standard mold techniques 
such as embossing or injection molding. The metals are 
selectively removed from the tips of the needles using 
electropolishing techniques, in which an applied anodic 35 
potential in an electrolytic solution will cause dissolution of 
metals more rapidly at sharp points, due to concentration of 
electric field lines at the sharp points. Once the underlying 
silicon needle forms have been exposed at the tips, the 
silicon is selectively etched away to form hollow metallic 40 
needle structures. This process could also be used to make 
hollow needles made from other materials by depositing a 
material other than metal on the needle forms and following 
the procedure described above. 
A preferred method of fabricating hollow metal micron- 45 
eedles utilizes micromold plating techniques, for example 
which are described as follows and in Examples 4 and 5. In 
a method for making metal microtubes, which does not 
require dry silicon etching, a photo-defined mold first is first 
produced, for example, by spin casting a thick layer, typi- 50 
cally 150 µm, of an epoxy (e.g., SU-8) onto a substrate that 
has been coated with a thin sacrificial layer, typically about 
10 to 50 nm. Arrays of cylindrical holes are then photolitho-
graphically defined through the epoxy layer, which typically 
is about 150 µm thick. (Despont, et al., "High-Aspect-Ratio, 55 
Ultra thick, Negative-Tone Near-UV Photoresist for 
MEMS," Proc. of IEEE lO'h Annual International Workshop 
on MEMS, Nagoya, Japan, pp. 518-522 (Jan. 26-30, 1997)). 
The diameter of these cylindrical holes defines the outer 
diameter of the tubes. The upper surface of the substrate, the 60 
sacrificial layer, is then partially removed at the bottom of 
the cylindrical holes in the photoresist. The exact method 
chosen depends on the choice of substrate. For example, the 
process has been successfully performed on silicon and glass 
substrates (in which the upper surface is etched using 65 
isotropic wet or dry etching techniques) and copper-clad 
printed wiring board substrates. In the latter case, the copper 
The rate and duration of electroplating is controlled in order 
to define the wall thickness and inner diameter of the 
microtubes. In one embodiment, this method was used to 
produce microtubes having a height of between about 150 
and 250 µm, an outer diameter of between about 40 and 120 
µm, and an inner diameter of between about 30 and 110 µm 
(i.e., having a wall thickness of 10 µm). In a typical array, 
the microtubes have a tube center-to-center spacing of about 
150 µm, but can vary depending on the desired needle 
density. 
A variation of this method is preferred for forming tapered 
microneedles. As described above, photolithography yields 
holes in the epoxy which have vertical sidewalls, such that 
the resulting shafts of the microneedles are straight, not 
tapered. This vertical sidewall limitation can be overcome 
by molding a preexisting 3D structure, i.e., a mold-insert. 
The subsequent removal of the mold-insert leaves a mold 
which can be surface plated similarly to the holes produced 
by photolithography described above. 
Alternatively, non-vertical sidewalls can be produced 
directly in the polymeric mold into which electroplating will 
take place. For example, conventional photoresists known in 
the art can be exposed and developed in such as way as to 
have the surface immediately adjacent to the mask be wider 
than the other surface. Specialized greyscale photoresists in 
combination with greyscale masks can accomplish the same 
effect. Laser-ablated molds can also be made with tapered 
sidewalls, e.g., by optical adjustment of the beam (in the 
case of serial hole fabrication) or of the reticle or mold 
during ablation (in the case of projection ablation). 
To form hollow tapered microneedles, the mold-insert is 
an array of solid silicon microneedles, formed as described 
in Henry, et al., "Micromachined Needles for the Transder-
mal Delivery of Drugs," Micro Electro Mechanical Systems, 
Heidelberg, Germany, Jan. 26-29, pp. 494-498 (1998). 
First, a layer of a material, such as an epoxy (e.g., SU-8), is 
spin cast onto the array of silicon microneedles to com-
pletely blanket the entire array. The epoxy settles during 
pre-bake to create a planar surface above the silicon needle 
tips; the material is then fully pre-baked, photolithographi-
cally cross-linked, and post-baked. 
The upper surface of the epoxy is then etched away, for 
example with an 0 2 /CHF3 plasma, until the needle tips are 
exposed, preferably leaving between about 1 and 5 µm of tip 
protruding from the epoxy. The silicon is then selectively 
removed, for example by using a SF 6 plasma or a HN031HF 
solution. The remaining epoxy micromold is the negative of 
the microneedles and has a small diameter hole where the tip 
of the microneedle formerly protruded. 
After the removal of the silicon, a seed layer, such as 
Ti-Cu-Ti is conformally sputter-deposited onto the epoxy 
micromold. Following the same process sequence described 
for hollow metal microtubes, one or more electroplatable 
metals or alloys, such as Ni, NiFe, Au, or Cu, are electro-
plated onto the seed layer. Finally, the epoxy is removed, for 
example by using an 0 2 /CHF3 plasma, leaving an array of 
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To control the transport of material out of or into the 
device through the microneedles, a variety of forces or 
mechanisms can be employed. These include pressure 
gradients, concentration gradients, electricity, ultrasound, 
receptor binding, heat, chemicals, and chemical reactions. 
Mechanical or other gates in conjunction with the forces and 
mechanisms described above can be used to selectively 
control transport of the material. 
In particular embodiments, the device should be "user-
hollow metal microneedles. In a preferred embodiment, this 
method is used to produce microneedles having a height of 
between about 150 and 250 µm, an outer diameter of 
between about 40 and 120 µm, and an inner diameter of 
between about 50 and 100 µm. In a typical array, the 5 
microtubes have a tube center-to-center spacing of about 
150 µm, but can vary depending on the desired needle 
density. The microneedles are 150 µm in height with a base 
diameter of 80 µm, a tip diameter of 10 µm, and a needle to 
needle spacing of 150 µm. 10 friendly." For example, in some transdermal applications, 
affixing the device to the skin should be relatively simple, 
and not require special skills. This embodiment of a micron-
eedle may include an array of microneedles attached to a 
housing containing drug in an internal reservoir, wherein the 
c. Silicon Dioxide Microneedles 
Hollow microneedles formed of silicon dioxide can be 
made by oxidizing the surface of the silicon microneedle 
forms (as described above), rather than depositing a metal 
and then etching away the solid needle forms to leave the 
hollow silicon dioxide structures. This method is illustrated 
15 housing has a bioadhesive coating around the microneedles. 
in FIGS. 4a-4d. FIG. 4a shows an array 24 of needle forms 
26 with masks 28 on their tips. In FIG. 4b, the needle forms 
26 have been coated with a layer 30 of metal, silicon dioxide 20 
or other material. FIG. 4c shows the coated needle forms 26 
The patient can remove a peel-away backing to expose an 
adhesive coating, and then press the device onto a clean part 
of the skin, leaving it to administer drug over the course of, 
for example, several days. 
a. Drug Delivery 
Essentially any drug or other bioactive agents can be 
delivered using these devices. Drugs can be proteins, 
enzymes, polysaccharides, polynucleotide molecules, and 
with the masks 28 removed. Finally, in FIG. 4d, the needle 
forms 26 have been etched away, leaving hollow needles 30 
made of metal, silicon dioxide, or other materials. 
In one embodiment, hollow, porous, or solid microneedles 
are provided with longitudinal grooves or other modifica-
tions to the exterior surface of the microneedles. Grooves, 
for example, should be useful in directing the flow of 
molecules along the outside of microneedles. 
25 synthetic organic and inorganic compounds. A preferred 
drug is insulin. Representative agents include anti-
infectives, hormones, growth regulators, drugs regulating 
cardiac action or blood flow, and drugs for pain control. The 
drug can be for local treatment or for regional or systemic 
d. Polymer Microneedles 
30 therapy. The following are representative examples, and 
disorders they are used to treat: 
In a preferred method, polymeric microneedles are made 
using microfabricated molds. For example, the epoxy molds 
can be made as described above and injection molding 35 
techniques can be applied to form the microneedles in the 
molds (Weber, et al., "Micromolding-a powerful tool for 
the large scale production of precise microstructures", Proc. 
SPIE-International Soc. Optical Engineer. 2879, 156-167 
(1996); Schift, et al., "Fabrication of replicated high preci- 40 
sion insert elements for micro-optical bench arrangements" 
Proc. SPIE- International Soc. Optical Engineer. 3513, 
122-134 (1998). These micromolding techniques are pre-
ferred over other techniques described herein, since they can 
provide relatively less expensive replication, i.e. lower cost 45 
of mass production. In a preferred embodiment, the polymer 
is biodegradable. 
4. Microneedle Device Applications 
The device may be used for single or multiple uses for 
rapid transport across a biological barrier or may be left in 50 
place for longer times (e.g., hours or days) for long-term 
transport of molecules. Depending on the dimensions of the 
device, the application site, and the route in which the device 
is introduced into (or onto) the biological barrier, the device 
may be used to introduce or remove molecules at specific 55 
locations. 
As discussed above, FIG. 1 shows a side elevational view 
of a schematic of a preferred embodiment of the micron-
eedle device 10 in a transdermal application. The device 10 
is applied to the skin such that the microneedles 12 penetrate 60 
through the stratum corneum and enter the viable epidermis 
so that the tip of the microneedle at least penetrates into the 
viable epidermis. In a preferred embodiment, drug mol-
ecules in a reservoir within the upper portion 11 flow 
through or around the microneedles and into the viable 65 
epidermis, where the drug molecules then diffuse into the 
dermis for local treatment or for transport through the body. 
Calcitonin, osteoporosis 
Enoxaprin, anticoagulant 
Etanercept, rheumatoid arthritis 
Erythropoietin, anemia 
Fentanyl, postoperative and chronic pain 
Filgrastin, low white blood cells from chemotherapy 
Heparin, anticoagulant 
Insulin, human, diabetes 
Interferon Beta I a, multiple sclerosis 
Lidocaine, local anesthesia 
Somatropin, growth hormone 
Sumatriptan, migraine headaches 
In this way, many drugs can be delivered at a variety of 
therapeutic rates. The rate can be controlled by varying a 
number of design factors, including the outer diameter of the 
microneedle, the number and size of pores or channels in 
each microneedle, the number of microneedles in an array, 
the magnitude and frequency of application of the force 
driving the drug through the microneedle and/or the holes 
created by the microneedles. For example, devices designed 
to deliver drug at different rates might have more micron-
eedles for more rapid delivery and fewer microneedles for 
less rapid delivery. As another example, a device designed to 
deliver drug at a variable rate could vary the driving force 
(e.g., pressure gradient controlled by a pump) for transport 
according to a schedule which was pre-programmed or 
controlled by, for example, the user or his doctor. The 
devices can be affixed to the skin or other tissue to deliver 
drugs continuously or intermittently, for durations ranging 
from a few seconds to several hours or days. 
One of skill in the art can measure the rate of drug 
delivery for particular microneedle devices using in vitro 
and in vivo methods known in the art. For example, to 
measure the rate of transdermal drug delivery, human 
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can be removed from the epidermis across the stratum 
corneum to assay for glucose concentration, which should 
be useful in aiding diabetics in determining their required 
insulin dose. Other substances or properties that would be 
5 desirable to detect include lactate (important for athletes), 
oxygen, pH, alcohol, tobacco metabolites, and illegal drugs 
(important for both medical diagnosis and law enforcement). 
cadaver skin mounted on standard diffusion chambers can be 
used to predict actual rates. See Hadgraft & Guy, eds., 
Transdermal Drug Delivery: Developmental Issues and 
Research Initiatives (Marcel Dekker, New York 1989); 
Bronaugh & Maibach, Percutaneous Absorption, 
Mechanisms-Methodology-Drug Delivery (Marcel 
Dekker, New York 1989). After filling the compartment on 
the dermis side of the diffusion chamber with saline, a 
microneedle array is inserted into the stratum corneum; a 
drug solution is placed in the reservoir of the microneedle 10 
device; and samples of the saline solution are taken over 
time and assayed to determine the rates of drug transport. 
In an alternate embodiment, biodegradable or non-
biodegradable microneedles can be used as the entire drug 
delivery device, where biodegradable microneedles are a 15 
preferred embodiment. For example, the microneedles may 
be formed of a biodegradable polymer containing a disper-
sion of an active agent for local or systemic delivery. The 
agent could be released over time, according to a profile 
determined by the composition and geometry of the 20 
microneedles, the concentration of the drug and other fac-
tors. In this way, the drug reservoir is within the matrix of 
one or more of the microneedles. 
The sensing device can be in or attached to one or more 
microneedles, or in a housing adapted to the substrate. 
Sensing information or signals can be transferred optically 
(e.g., refractive index) or electrically (e.g., measuring 
changes in electrical impedance, resistance, current, voltage, 
or combination thereof). For example, it may be useful to 
measure a change as a function of change in resistance of 
tissue to an electrical current or voltage, or a change in 
response to channel binding or other criteria (such as an 
optical change) wherein different resistances are calibrated 
to signal that more or less flow of drug is needed, or that 
delivery has been completed. 
In another alternate embodiment, these microneedles may 
be purposefully sheared off from the substrate after pen-
etrating the biological barrier. In this way, a portion of the 
microneedles would remain within or on the other side of the 
biological barrier and a portion of the micro needles and their 
substrate would be removed from the biological barrier. In 
the case of skin, this could involve inserting an array into the 
skin, manually or otherwise breaking off the microneedles 
tips and then remove the base of the microneedles. The 
portion of the microneedles which remains in the skin or in 
In one embodiment, one or more microneedle devices can 
be used for (1) withdrawal of interstitial fluid, (2) assay of 
the fluid, and/or (3) delivery of the appropriate amount of a 
therapeutic agent based on the results of the assay, either 
automatically or with human intervention. For example, a 
25 sensor delivery system may be combined to form, for 
example, a system which withdraws bodily fluid, measures 
its glucose content, and delivers an appropriate amount of 
insulin. The sensing or delivery step also can be performed 
using conventional techniques, which would be integrated 
30 into use of the microneedle device. For example, the micron-
eedle device could be used to withdraw and assay glucose, 
and a conventional syringe and needle used to administer the 
insulin, or vice versa. 
or across another biological barrier could then release drug 
over time according to a profile determined by the compo-
sition and geometry of the microneedles, the concentration 
35 In an alternate embodiment, microneedles may be pur-
posefully sheared off from the substrate after penetrating the 
biological barrier, as described above. The portion of the 
microneedles which remain within or on the other side of the 
biological barrier could contain one or more biosensors. For 
of the drug and other factors. In a preferred embodiment, the 
microneedles are made of a biodegradable polymer. The 
release of drug from the biodegradable microneedle tips 
could be controlled by the rate of polymer degradation. 40 
Microneedle tips could release drugs for local or systemic 
effect, but could also release other agents, such as perfume, 
insect repellent and sun block. 
Microneedle shape and content could be designed to 
control the breakage of microneedles. For example, a notch 45 
could be introduced into microneedles either at the time of 
example, the sensor could change color as its output. For 
microneedles sheared off in the skin, this color change could 
be observed through the skin by visual inspection or with the 
aid of an optical apparatus. 
Other than transport of drugs and biological molecules, 
the microneedles may be used to transmit or transfer other 
materials and energy forms, such as light, electricity, heat, or 
pressure. The microneedles, for example, could be used to 
direct light to specific locations within the body, in order that 
the light can directly act on a tissue or on an intermediary, 
fabrication or as a subsequent step. In this way, microneedles 
would preferentially break at the site of the notch. Moreover, 
the size and shape of the portion of microneedles which 
break off could be controlled not only for specific drug 
release patterns, but also for specific interactions with cells 
in the body. For example, objects of a few microns in size 
50 such as light-sensitive molecules in photodynamic therapy. 
are known to be taken up by macrophages. The portions of 
microneedles that break off could be controlled to be bigger 
The microneedles can also be used for aerosolization or 
delivery for example directly to a mucosal surface in the 
nasal or buccal regions or to the pulmonary system. 
or smaller than that to prevent uptake by macrophages or 55 
could be that size to promote uptake by macrophages, which 
could be desirable for delivery of vaccines. 
The microneedle devices disclosed herein also should be 
useful for controlling transport across tissues other than 
skin. For example, microneedles could be inserted into the 
eye across, for example, conjunctiva, sclera, and/or cornea, 
to facilitate delivery of drugs into the eye. Similarly, micron-
eedles inserted into the eye could facilitate transport of fluid b. Diagnostic Sensing of Body Fluids (Biosensors) 
One embodiment of the devices described herein may be 
used to remove material from the body across a biological 
barrier, i.e. for minimally invasive diagnostic sensing. For 
example, fluids can be transported from interstitial fluid in a 
tissue into a reservoir in the upper portion of the device. The 
fluid can then be assayed while in the reservoir or the fluid 
can be removed from the reservoir to be assayed, for 
diagnostic or other purposes. For example, interstitial fluids 
60 out of the eye, which may be of benefit for treatment of 
glaucoma. Microneedles may also be inserted into the buc-
cal (oral), nasal, vaginal, or other accessible mucosa to 
facilitate transport into, out of, or across those tissues. For 
example, a drug may be delivered across the buccal mucosa 
65 for local treatment in the mouth or for systemic uptake and 
delivery. As another example, microneedle devices may be 
used internally within the body on, for example, the lining 
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of the gastrointestinal tract to facilitate uptake of orally-
ingested drugs or the lining of blood vessels to facilitate 
penetration of drugs into the vessel wall. For example, 
cardiovascular applications include using microneedle 
devices to facilitate vessel distension or immobilization, 
similarly to a stent, wherein the microneedles/substrate can 
function as a "staple-like" device to penetrate into different 
tissue segments and hold their relative positions for a period 
of time to permit tissue regeneration. This application would 
be particularly useful with biodegradable devices. These 
uses may involve invasive procedures to introduce the 
microneedle devices into the body or could involve 
swallowing, inhaling, injecting or otherwise introducing the 
devices in a non-invasive or minimally-invasive manner. 
20 
the wafers and the underlying platen (Apiezon N, K. J. 
Lesker, Clairton, Pa.). The wafers were etched using the 
following gases and conditions: SF 6 (20 standard cubic 
centimeters per minute) and 0 2 (15 standard cubic centime-
s ters per minute) at a pressure of 150 mTorr and a power of 
150 W for a run time of approximately 250 minutes. These 
conditions caused both deep vertical etching and slight 
lateral underetching. By controlling the ratio of flow rates of 
the SF 6 and 0 2 gases used to form the plasma, the aspect 
10 
ratio of the microneedles could be adjusted. The regions 
protected by the chromium masks remained and formed the 
microneedles. Etching was allowed to proceed until the 
masks fell off due to underetching, resulting in an array of 
sharp silicon spikes. 
EXAMPLE 2 
Transdermal Transport Using Solid Microneedles 
The present invention will be further understood with 15 
reference to the following non-limiting examples. 
To determine if microfabricated microneedles could be 
used to enhance transdermal drug delivery, arrays of micron-
eedles were made using a deep plasma etching technique. 
20 Their ability to penetrate human skin without breaking was 
tested and the resulting changes in transdermal transport 
were measured. 
EXAMPLE 1 
Fabrication of Solid Silicon Microneedles 
Arrays of microneedles were fabricated having extremely 
sharp tips (radius of curvature less than 1 µm), and are 
A chromium masking material was deposited onto silicon 
wafers and patterned into dots having a diameter approxi-
mately equal to the base of the desired microneedles. The 
wafers were then loaded into a reactive ion etcher and 
subjected to a carefully controlled plasma based on fluorine/ 
oxygen chemistries to etch very deep, high aspect ratio 
valleys into the silicon. Those regions protected by the metal 
mask remain and form the microneedles. 
<100>-oriented, prime grade, 450--550 µm thick, 10-15 
Q-cm silicon wafers (Nova Electronic Materials Inc., 
Richardson, Tex.) were used as the starting material. The 
wafers were cleaned in a solution of 5 parts by volume 
deionized water, 1 part 30% hydrogen peroxide, and I part 
30% ammonium hydroxide (J. T. Baker, Phillipsburg, N.J.) 
25 approximately 150 µm long. Because the skin surface is not 
fiat due to dermatoglyphics and hair, the full length of these 
microneedles will not penetrate the skin. All experiments 
were performed at room temperature (23±2° C). 
The ability of the microneedles to pierce skin without 
30 breaking was then tested. Insertion of the arrays into skin 
required only gentle pushing. Inspection by light and elec-
tron microscopy showed that more than 95% of micron-
eedles within an array pierced across the stratum corneum of 
the epidermis samples. Moreover, essentially all of the at approximately 80° C. for 15 minutes, and then dried in an 
oven (Blue M Electric, Watertown, Wis.) at 150° C. for 10 
minutes. Approximately 1000 A of chromium (Mat-Vac 
Technology, Flagler Beach, Fla.) was deposited onto the 
wafers using a DC-sputterer (601 Sputtering System, CVC 
Products, Rochester, N.Y.). The chromium layer was pat-
terned into 20 by 20 arrays of 80 µm diameter dots with 150 40 
µm center-to-center spacing using the lithographic process 
described below. 
35 microneedles that penetrated the epidermis remained intact. 
On those very few which broke, only the top 5-10 µm was 
damaged. Microneedle arrays could also be removed with-
out difficulty or additional damage, as well as re-inserted 
into skin multiple times. 
To quantitatively assess the ability of microneedles to 
increase transdermal transport, calcein permeability of 
human epidermis with and without inserted microneedle 
arrays was measured. Calcein crosses skin very poorly under 
normal circumstances and therefore represents an especially 
A layer of photosensitive material (1827 photoresist, 
Shipley, Marlborough, Mass.) was deposited onto the chro-
mium layer covering the silicon wafers. A standard litho-
graphic mask (Telic, Santa Monica, Calif.) bearing the 
appropriate dot array pattern was positioned on top of the 
photoresist layer. The wafer and photoreist were then 
exposed to ultraviolet (UV) light through the mask by means 
45 difficult compound to deliver. As expected, passive perme-
ability of calcein across unaltered skin was very low, indi-
cating that the epidermis samples were intact. 
Insertion of microneedles into skin was capable of dra-
matically increasing permeability to calcein. When micron-
so eedles were inserted and left embedded in the skin, calcein 
permeability was increased by more than 1000-fold. Inser-
tion of microneedles for 10 s, followed by their removal, 
yielded an almost 10,000-fold increase. Finally, insertion of 
a microneedle array for 1 h, followed by its removal, 
of an optical mask aligner (Hybralign Series 500, Optical 
Associates, Inc., Milpitas, Calif.). The exposed photoresist 
was removed by soaking the wafers in a liquid developer 
(354 developer, Shipley, Marlborough, Mass.) leaving the 
desired dot array of photoresist on the chromium layer. 
Subsequently, the wafers were dipped into a chromium 
etchant (CR-75; Cyanteck Fremont, Calif.), which etched 
the chromium that had been exposed during the photolithog-
raphy step, leaving dot arrays of chromium (covered with 
photoresist) on the surface of the silicon wafer. The photo-
resist still present on the chromium dots formed the masks 60 
needed for fabrication of the micro needles, described below. 
ss increased skin permeability by about 25,000-fold. Perme-
abilities for skin with microneedles inserted and then 
The microneedles were fabricated using a reactive ion 
etching techniques based on the Black Silicon Method 
developed at the University ofTwente. The patterned wafers 
were etched in a reactive ion etcher (700 series wafer/batch 65 
Plasma Processing System, Plasma Therm, St. Petersburg, 
Fla.) with means for ensuring good thermal contact between 
removed are higher than for skin with microneedles remain-
ing embedded probably because the microneedles them-
selves or the silicon plate supporting the array may block 
access to the microscopic holes created in the skin. Light 
microscopy showed that the holes which remained in the 
skin after microneedles were removed were approximately 1 
µmin size. 
To confirm in vitro experiments which showed that skin 
permeability can be significantly increased by microneedles, 
studies were conducted with human volunteers. They indi-
cated that microneedles could be easily inserted into the skin 
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of the forearm or hand. Moreover, insertion of microneedle 
arrays was never reported to be painful, but sometimes 
elicited a mild "wearing" sensation described as a weak 
pressure or the feeling of a piece of tape affixed to the skin. 
Although transport experiments were not performed in vivo, 5 
skin electrical resistance was measured before and after 
microneedle insertion. Microneedles caused a 50-fold drop 
spacing of 150 µm. The holes in the interior of the micro-
tubes protrude through the base metal supporting the tubes. 
EXAMPLE 5 
Micromold Fabrication of Tapered Microneedles 
A micromold having tapered walls was fabricated by 
molding a preexisting 3-D array of microneedles, i.e. the 
mold-insert, and subsequently removing the mold insert. 
The micromold was then surface plated in a manner similar 
to that for the microtubes described in Example 4. The 
fabrication sequence is illustrated in FIGS. 7a-7d. 
First, an array of solid silicon microneedles 50 were 
prepared as described in Henry, et al., "Micromachined 
Needles for the Transdermal Delivery of Drugs," Micro 
in skin resistance, a drop similar to that caused by the 
insertion of a 30-gauge "macroneedle." Inspection of the site 
immediately after microneedle insertion showed no holes 10 
visible by light microscopy. No erythema, edema or other 
reaction to microneedles was observed over the hours and 
days which followed. This indicates that microneedle arrays 
can permeabilize skin in human subjects in a non-painful 
and safe manner. 15 Electro Mechanical Systems, Heidelberg, Germany, Jan. 26-29, pp. 494-498 (1998). Then, a layer of epoxy 52 
(SU-8) was spin cast onto the microneedle array to com-
pletely blanket the array (FIG. 7a). The epoxy S2 settled 
during pre-bake to create a planar surface above the tips of 
EXAMPLE 3 
Fabrication of Silicon Microtubes 
Three-dimensional arrays of microtubes were fabricated 
from silicon, using deep reactive ion etching combined with 
a modified black silicon process in a conventional reactive 
ion etcher. The fabrication process is illustrated in FIGS. 
Sa-d. First, arrays of 40 µm diameter circular holes 32 were 
patterned through photoresist 34 into a 1 µm thick Si02 layer 
36 on a two inch silicon wafer 3S (FIG. Sa). The wafer 3S 
was then etched using deep reactive ion etching (DRIE) 
(Laermer, et al., "Bosch Deep Silicon Etching: Improving 
Uniformity and Etch Rate for Advanced MEMS 
Applications," Micro Electro Mechaiical Systems, Orlando, 
Fla., USA (Jan. 17-21, 1999)). in an inductively coupled 
plasma (ICP) reactor to etch deep vertical holes 40. The deep 
silicon etch was stopped after the holes 40 are approximately 
200 µm deep into the silicon substrate 3S (FIG. Sb) and the 
photoresist 34 was removed. A second photolithography step 
patterned the remaining Si02 layer 36 into circles concentric 
to the holes, thus leaving ring shaped oxide masks 34 
surrounding the holes (FIG. Sc). The photoresist 34 was then 
removed and the wafer 3S was again deep silicon etched, 
while simultaneously the holes 40 were etched completely 
through the wafer 3S (inside the Si02 ring) and the silicon 
was etched around the Sio2 ring 3S leaving a cylinder 42 
(FIG. Sd.). The resulting tubes were 150 µm in height, with 
an outer diameter of 80 µm, an inner diameter of 40 µm, and 
a tube center-to-center spacing of 300 µm. 
EXAMPLE 4 
Micromold Fabrication of Metal Microtubes 
Hollow metal microtubes were prepared without dry 
silicon etching, using a thick, photo-defined mold of epoxy. 
The sequences are illustrated in FIGS. 6a-e. First, a thick 
layer of SU-8 epoxy 44 was spin cast onto a silicon or glass 
substrate 46 that had been coated with 30 nm of titanium 4S, 
the sacrificial layer. Arrays of cylindrical holes 49 were then 
photolithographically defined through an epoxy layer 44, 
typically 150 µm thick (FIG. 6a). The sacrificial layer then 
was partially removed using a wet etching solution contain-
ing hydrofluoric acid and water at the bottom of the cylin-
drical holes in the SU-8 photoresist 46 (FIG. 6b). A seed 
layer of Ti/Cu/Ti (30 nm/200 nm/30 nm) 39 was then 
conformally DC sputter-deposited onto the upper surface of 
the epoxy mold and onto the sidewalls of the cylindrical 
holes 49 (FIG. 6c). As shown in FIG. 6c, the seed layer 39 
was electrically isolated from the substrate. Subsequently, 
NiFe was electroplated onto the seed layer 39 (FIG. 6d.), the 
epoxy 44 was removed from the substrate, and the surround-
ing epoxy 44 was removed (FIG. 6e). The resulting micro-
tubes are 200 µm in height with an outer diameter of 80 lm, 
an inner diameter of 60 µm, and a tube center-to-center 
20 
the microneedles SO. The epoxy S2 was then fully pre-baked, 
photolithographically cross-linked, and post-baked. 
25 
Then, the upper surface of the epoxy 52 was etched away 
using an 0 2/CHF3 plasma until approximately 1 to 2 µm of 
the needle tips S4 were exposed, protruding from the epoxy 
S2 (FIG. 7b). The silicon was then selectively removed by 
using a SF6 plasma (FIG. 7c). The remaining epoxy mold S2 
provided a negative of the microneedles with a small diam-
eter hole where the tip of the silicon needle protruded. After 
the removal of the silicon, a seed layer of Ti-Cu-Ti S4 
30 
was conformally sputter-deposited onto the top and side-
walls of the epoxy micromold S2. Following the same 
process sequence as described in Example 4, NiFe was then 
electroplated onto the seed layer S4 (FIG. 7c). Finally, the 
epoxy was removed using an 0 2/CHF3 plasma, leaving a 
35 
20x20 array of NiFe hollow metal microneedles S4 (FIG. 
7d). The microneedles S4 were 150 µmin height with a base 
diameter of 80 µm, a tip diameter of 10 µm, and a needle to 
needle spacing of 150 µm. 
EXAMPLE 6 
40 Micromold Fabrication of Tapered Microneedles Using 
Laser-Formed Molds 
A micromold having tapered walls was fabricated by use 
of laser ablation techniques, as shown in FIGS. Sa-d. A 
laser-ablatable polymer sheet 60 such as KAPTON™ 
45 polymide approximately 150 microns in thickness was 
optionally laminated to a thin (10-30 micron) metal sheet 62 
such as titanium (FIG. Sa). A tapered bole 64 was formed in 
the metal/polymer laminate 60/62 using a laser technique 
such as excimer laser ablation (FIG. Sb). The entry hole of 
50 the laser spot was on the metal side 62, and a through hole 
was made through both the metal sheet and the polymer film. 
The through hole 64 was tapered in combination with either 
defocusing or appropriate substrate motion to create a taper 
such that the wide end of the hole 64 (typically 40-50 
55 microns) was on the metal side 62 and the narrow end of the 
hole 64 (typically 10-20 microns) was on the polymer 60 
side. A thin layer of metal 66, e.g. titanium, of thickness 0.1 
micron was then deposited, e.g., using a sputter-deposition 
technique, in such a way that the metal 66 deposited on the 
60 metal film side and coated the polymer sidewalls, but did not 
coat the polymer 60 side of the laminate (FIG. Sc). Elec-
trodeposition of metal 6S, e.g., gold, to a thickness of 1-5 
microns was then performed on the titanium-coated metal 
surface 66, and polymer sidewalls curved section of 60 next 
65 to 64. Finally, the polymer 60 was removed, using e.g. an 
oxygen plasma, to form the completed microneedles (FIG. 
Sd). 
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23 24 
permeabilities were measured, indicating that the micron-
eedles had created pathways for transport across the skin. 
Furthermore, in all cases, when solid microneedles were 
inserted into the skin and then removed, even greater skin 
Alternate polymer removal methods, such as thermal, 
solvent, aqueous, or phodegradation followed by solvent or 
aqueous removal, are also possible if the polymer material 
is chosen appropriately (e.g., a photoresist resin). 
EXAMPLE 7 
Formation of Microneedles by Embossing 
Formation of a microneedle by embossing is shown in 
FIGS. 9a-9f. A polymeric layer 70 (FIG. 9a) is embossed by 
a solid microneedle or microneedle array 72 (FIG. 9b). The 
array 72 is removed (FIG. 9c), and the layer 70 is etched 
from the non-embossed side 74 until the embossed cavity 76 
5 permeabilities resulted. Finally, when hollow microneedles 
were inserted into the skin and left in place, still greater skin 
permeabilities resulted for those compounds tested. These 
studies show that microneedles can dramatically increase 
skin permeability and can thereby increase transport of a 
is exposed (FIG. 9d). A metallic layer 78 is then deposited 
10 
number of different compounds across the skin. It also 
shows that when solid microneedles are used, a preferred 
embodiment involves inserting and then removing 
microneedles, rather than leaving them in place. It also 
shows that using hollow microneedles are a preferred on the embossed side and the sidewalls, but not on the 
non-embossed side 74 (FIG. 9e). This layer 78 is optionally 15 
thickened by electrodeposition of an additional metal layer 
80 on top of it (FIG. 9e). The polymer layer 70 is then 
removed to form the microneedles 78/80 (FIG. 9/). 
EXAMPLE 8 
Transdermal Application of Hollow Microneedles 
The bore of hollow microneedles must provide fluid flow 
with minimal clogging in order to be suitable to transport 
material, such as in transdermal drug delivery. Therefore, 
microneedies and microtubes were evaluated to determine 
their suitability for these functions. 
20 
25 
30 
embodiment over the use of solid microneedles. 
In Table 2, the flow rate of water through hollow silicon 
microneedles is shown as a function of applied pressure. 
These data demonstrate that significant flow rates of water 
through microneedles can be achieved at modest pressures. 
TABLE 1 
Transport of Drugs through Microneedles inserted into Skin. 
Solid needles 
No Solid needles inserted and Hollow needles 
Compound needles inserted removed inserted 
Calcein delivery 4 x 10-3 1 x 10-2 1 x 10-1 
Calcein removal 2 x 10-3 1 x 10-2 n.a. 
Insulin delivery 1 x 10-4 1 x 10-2 n.a. 
Bovine serum 9 x 10-4 8 x 10-3 9 x 10-2 
albumin 
delivery 
Nanoparticle n.a. 3 x 10-5 n.a. 
delivery 
Hollow metal and silicon microneedles, produced as 
described in Examples 3-5, were inserted through human 
skin epidermis with no apparent clogging of the needle 
bores. Scanning electron microscopy of a hollow metal 
(NiFe) microneedle penetrating up through the underside of 
human epidermis showed the microneedle remains intact, 
with the tip free of debris. Similarly, silicon microneedles, 
metal microneedles, and metal microtubes were successfully 
inserted through human skin. Also, the hollow microneedles 
were shown to permit the flow of water through their bores. 
**means that the transport was below the detection limit. 
n.a. means that the data are not available. 
35 Nanoparticles were made of latex with a diameter of approximately 100 
nm. 
EXAMPLE 9 
Transport of Drugs through Microneedles Inserted into Skin 
Studies were performed with solid and hollow micron-
eedles to demonstrate transport of molecules and fluids. As 40 
shown in Table 1, transport of a number of different com-
pounds across skin is possible using microneedles. These 
studies were performed using either solid silicon micron-
eedles or using hollow silicon microneedles made by meth-
ods described in this patent. Transport was measured across 45 
human cadaver epidermis in vitro using Franz diffusion 
chambers at 37° C. using methods described in S. Henry, D. 
McAllister, M. G. Allen and M. R. Prausnitz. Microfabri-
cated microneedles: A novel method to increase transdermal 
drug delivery. J. Pharm. Sci. 87, 922-925 (1998). 50 
The transdermal delivery of calcein, insulin, bovine serum 
albumin and nanoparticles was measured. Delivery refers to 
the ability to transport these compounds from the stratum 
corneum side of the epidermis to the viable epidermis side. 
This is the direction of transport associated with delivering 55 
drugs into the body. Removal of calcein was also measured. 
Removal refers to the ability to transport calcein from the 
viable epidermis side of the epidermis to the stratum cor-
neum side. This is the direction of transport associated with 
removing from the body compounds found in the body, such 60 
as glucose. 
In all cases shown in Table 1, transport of these com-
pounds across skin occurred at levels below our detection 
limit when no needles were inserted into the skin. Intact skin 
provides an excellent barrier to transport of these com- 65 
pounds. In all cases examined, when solid microneedles 
were inserted into the skin and left in place, large skin 
TABLE 2 
Flow rate of water through hollow silicon microneedles 
as a function of applied pressure 
Pressure (psi) Flow rate (ml/min) 
1.0 16 
1.5 24 
2.0 31 
2.5 38 
3.0 45 
Publications cited herein and the material for which they 
are cited are specifically incorporated by reference. 
Those skilled in the art will recognize, or be able to 
ascertain using no more than routine experimentation, many 
equivalents to the specific embodiments of the invention 
described herein. Such equivalents are intended to be 
encompassed by the following claims. 
We claim: 
1. A method for making a microneedle device having a 
substrate to which a plurality of microneedles are attached or 
integrally formed, the method comprising 
(i) forming a micromold having sidewalls which define a 
surface of each of the microneedles; and 
(ii) using the micromold to form the microneedles and the 
substrate, wherein the microneedles extend at an angle 
from the substrate. 
2. The method of claim 1 wherein the micromold is 
formed by a process which includes providing a mold 
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substrate and then forming a plurality of holes in the mold 
substrate, thereby forming the micromold wherein the inner 
surfaces of the holes define the sidewalls which correspond 
to outer surfaces of each of the microneedles. 
3. The method of claim 2 wherein the holes are photo- 5 
lithographically defined. 
4. The method of claim 2 wherein the holes are defined 
using a laser technique. 
5. The method of claim 4 wherein the laser technique is 
laser ablation. 10 
26 
(b) removing a part of the layer of removable material to 
expose the tips of the microneedles of the mold-insert, 
and 
(c) removing the mold-insert to yield a micromold. 
15. The method of claim 14 further comprising 
( d) applying a metal, or other material having properties 
distinct from the material forming the micromold, onto 
the micromold to form the microneedles, and 
( e) removing the micro mold from the micro needles. 
16. The method of claim 14 wherein the micromold is 
removed using a process selected from the group consisting 
of oxygen plasma, thermal, solvent, aqueous, and photodeg-
radation removal techniques. 
6. The method of claim 1 comprising, in step (ii), applying 
a metal, or other material having different properties than the 
material forming the micromold, to the sidewalls to form 
hollow microneedles, and then removing the micromold 
from the microneedles. 
17. The method of claim 1 wherein the micro mold is 
15 shaped by embossing. 
7. The method of claim 6 wherein the metal or other 
material is applied by a sputter-deposition technique or a 
electrodeposition technique. 
8. The method of claim 6 wherein the micromold is 
removed using a process selected from the group consisting 20 
of oxygen plasma, thermal, solvent, aqueous, and photodeg-
radation removal techniques. 
9. The method of claim 6 wherein the metal or other 
material is applied by electroless plating. 
10. The method of claim 1 comprising, in step (ii), filling 25 
the micromold with a fluid material that is hardened in the 
micromold to form the microneedles. 
11. The method of claim 10 which utilizes injection 
molding or reaction injection molding. 
18. The method of 1 wherein the micromold is shaped 
using a laser to selectively remove material. 
19. The method of claim 18 wherein the material is a 
polymer/metal laminante. 
20. The method of claim 1 wherein the angle is about 90°. 
21. The method of claim 2 wherein the microneedle is 
formed of a metal selected from the group consisting of 
nickel, iron, gold, titanium, copper, platinum, palladium, 
stainless steels, and alloys thereof. 
22. The method of claim 1 wherein the micromold is 
formed of a polymeric material. 
23. The method of claim 1 wherein the microneedles 
comprise a polymer. 
24. The method of claim 1 wherein the micromold formed 
12. The method of claim 1 wherein, in step (i), the 
micromold is fabricated by forming a mold from a mold-
insert. 
13. The method of claim 12 wherein the mold insert is an 
30 in step (i) is in the form of an array of mold microneedles, 
wherein the outer surfaces of each of the mold micro needles 
correspond to the sidewalls which define the inner surface of 
hollow microneedles; and 
array of microneedles. 
14. The method of claim 13 for forming hollow 35 
microneedles, comprising the steps of 
(a) layering a removable material onto the array to cover 
the microneedles of the mold-insert, 
wherein, in step (ii), the array is coated with a material 
forming the microneedles and the substrate of the 
device, and then the micromold is removed. 
* * * * * 
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